as 05-17-2024 4:00pm EST
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies.
Founded: | 2011 | Country: | United States |
Employees: | N/A | City: | BERKELEY |
Market Cap: | 319.7M | IPO Year: | 2021 |
Target Price: | $20.67 | AVG Volume (30 days): | 1.7M |
Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -1.46 | EPS Growth: | N/A |
52 Week Low/High: | $3.37 - $8.59 | Next Earning Date: | 05-07-2024 |
Revenue: | $33,404,000 | Revenue Growth: | 127.41% |
Revenue Growth (this year): | -63.69% | Revenue Growth (next year): | 5.68% |
CRBU Breaking Stock News: Dive into CRBU Ticker-Specific Updates for Smart Investing
Simply Wall St.
11 days ago
MT Newswires
11 days ago
Zacks
12 days ago
GlobeNewswire
12 days ago
GlobeNewswire
18 days ago
GlobeNewswire
25 days ago
GlobeNewswire
a month ago
GlobeNewswire
a month ago